Honorable Mention: Continuous Implantable Peritoneal Ultrafiltration Device for Inter-treatment Volume Control in Hemodialysis Treated Patients

Inter-dialytic weight gain is a major cause of complications in hemodialysis (HD) treatment, including hemodynamic shock, arrhythmia and heart failure exacerbation. The tendency of dialysis patients to accumulate fluid must be managed through dietary limitations and ultrafiltration during dialysis sessions, both hindered by patient adherence, fluid status assessment and dialysis sessions duration. Achieving balance between chronic hypervolemia and acute hypotension remains a big challenge. Excessive ultrafiltration rates during HD sessions imply of higher morbidity and mortality, requiring HD to be carefully and slowly administered.

Paragate has developed the IPUD, an implantable peritoneal ultrafiltration device, that acts as a mechanical bypass of the kidneys. By continuously inducing controlled hydrostatic pressure gradient onto the peritoneal membranes, systemic isotonic (electrolytes and toxins) fluid is drawn from the neighboring tissues and slowly drained through the urinary system, independently of the kidney function. The device can be wirelessly configured per patient needs, while monitoring and remotely streaming patient data, including congestion surrogate markers, through a dedicated management tool. The performance of the system, being developed for treatment of fluid overload in heart failure patients, was demonstrated in small and large animals' studies for period of two months, representing the major tissue growth phase post implantation.

The IPUD technology may provide a tool for continuous isotonic fluid removal at home, between treatments, thus – minimizing baseline congestion, allowing to significantly shorten HD sessions duration while also providing additional renal capacity to the patients. Such inter-dialytic volume control (IDVC) therapy carries potential improvement in patients' QoL.

To learn more, please visit www.paragate-medical.com.